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A B S T R A C T
Infantile spasms (IS) is a developmental and epileptic encephalopathy with heterogeneous etiologies including
many genetic causes. Genetic studies have identified pathogenic variants in over 30 genes as causes of IS. Many
of these genetic causes are extremely rare, with only one reported incidence in an individual with IS. To better
understand the genetic landscape of IS, we used targeted sequencing to screen 42 candidate IS genes and 53
established developmental and epileptic encephalopathy genes in 92 individual with IS. We identified a genetic
diagnosis for 7.6% of our cohort, including pathogenic variants in KCNB1 (n=2), GNAO1 (n= 1), STXBP1
(n=1), SLC35A2 (n=1), TBL1XR1 (n=1), and KIF1A (n= 1). Our data emphasize the genetic heterogeneity
of IS and will inform the diagnosis and management of individuals with this devastating disorder.
1. Introduction
Infantile spasms (IS) are a relatively common type of epileptic sei-
zure, usually beginning in the early infantile period and characterized
by clusters of flexion or extension limb and trunk spasms. These spasms
are often accompanied by the electroencephalography (EEG) pattern of
hypsarrhythmia. Despite advances in the early diagnosis and treatment
of IS, the neurodevelopmental outcome for patients remains poor. IS
frequently leads to developmental arrest or regression, intellectual
disabilities, and/or chronic refractory seizures (Pellock et al., 2010).
The etiology of IS is highly heterogeneous, in part because IS can be
the clinical expression of a variety of genetic or acquired conditions.
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Major causes of IS include extrinsic brain injuries, metabolic en-
cephalopathies, brain malformations, and chromosomal abnormalities;
however, approximately 30% of cases remain unexplained (Pellock
et al., 2010). Genetic studies of individuals with unexplained IS have
identified pathogenic variants in over 30 genes (McTague et al., 2016),
many of which are also associated with other seizure types. Variants in
these genes only account for 11–29% of unsolved IS cases (Boutry-
Kryza et al., 2015; Epi et al., 2013; Michaud et al., 2014), suggesting
that many IS genes have yet to be identified.
We performed targeted massively parallel sequencing of 42 candi-
date IS genes and 53 established developmental and epileptic en-
cephalopathy (DEE) genes in 92 individuals with IS. We identified pa-
thogenic variants in 7.6% of our cohort. KCNB1 was the only gene
where pathogenic variants were found in more than one individual.
2. Methods
2.1. Cohort
Individuals recruited through the EuroEPINOMICS-RES consortium
for the project on non-lesional epileptic spasms (NLES) were enrolled
by 10 clinical sites in 9 different European countries. Inclusion criteria
included documented infantile spasms with onset in the first 2 years of
life, normal routine metabolic screening, and absence of epileptogenic
lesion on brain MRI. Most individuals had undergone testing for known
genetic causes of infantile spasms, but this was not required for study
inclusion. Individuals with a family history of epilepsy in first-degree
relatives were excluded. Genomic DNA of the individuals was extracted
from peripheral blood according to standard procedures. The study was
approved by the local ethics committee of each participating center.
Parents or the legal guardian of each study participant signed an in-
formed consent form for participation.
2.2. Gene selection for targeted sequencing
We selected 95 genes for sequence analysis: 39 genes in which at
least one individual with IS was reported to have a de novo variant in
another study (Conti et al., 2015; Endele et al., 2010; Epi et al., 2013;
Euro et al., 2014; Helbig et al., 2018; Ishii et al., 2017; Langlois et al.,
2016; Michaud et al., 2014; Saitsu et al., 2014); three candidate IS
genes located in pathogenic copy number variants; and 53 established
DEE genes to ensure uniform testing across the cohort. A complete list
of genes sequenced in this study can be found in Supplementary
Table 1.
2.3. Targeted sequencing of candidate genes
Molecular inversion probes (MIPs) or single molecule MIPs
(smMIPs) were use to target all coding exons and intron/exon
boundaries (5 flanking base pairs) of each of the 95 target genes.
Library preparation, sequencing, and processing were performed as
previously described (Myers et al., 2017). A read-depth of 50X (MIPs)
or 8X (smMIPs) and an allele balance of greater than 25% (MIPS) or
15% (smMIPs) were required for accurate variant calling. Variants not
predicted to impact protein coding sequence (synonymous and intronic)
and variants present (AC > 3) in genome Aggregation Database
(gnomAD v2.1.1), or with an allele frequency> 1% for recessive ana-
lysis, were excluded from further analysis.
2.4. Criteria for pathogenicity
Segregation analysis was carried out on all rare protein effecting
variants by targeted sequencing. Variants were considered pathogenic
or likely-pathogenic according to ACMG guidelines(Richards et al.,
2015). In all families with an identified de novo mutation, we used
microsatellite analysis (PowerPlex S5 system, Promega) or targeted
capture (smMIPs) of an in house 51 single nucleotide polymorphism
(SNP) marker set to confirm relatedness of the trio. All reported var-
iants were validated by Sanger sequencing.
3. Results
We sequenced candidate or known IS genes in a cohort of 92 in-
dividuals with unexplained IS. On average, 84% of the target was
covered above the threshold needed for accurate variant calling
(Supplementary Table 1). Pathogenic variants were identified in 7 of
the 92 individuals (7.6%) (Table 1). These variants were distributed
over 6 of the 95 genes screened (GNAO1, KCNB1, KIF1A, SLC35A2,
STXBP1, and TBL1XR1). KCNB1 was the only gene where pathogenic
variants were found in more than one individual (n=2). Variants of
uncertain significance were identified in FASN, HDAC4, PNMAL1, and
PPP3CA (Table 1). Detailed phenotyping information for individuals for
whom we have identified a causative variant can be found in Table 2.
4. Discussion
This study confirms the genetic heterogeneity of IS. We identified a
genetic etiology for 7.6% of individuals in our series, with variants in
no single gene accounting for greater than 3% of our cohort. We
identified 5 pathogenic variants in 4 established IS genes, KCNB1,
GNAO1, STXBP1, and SLC35A2. Of the 42 candidate IS genes we
screened, we identified pathogenic variants in two genes TBL1XR1
(MIM: 608628) and KIF1A (MIM: 601255).
Transducin β-like 1 X-linked receptor 1 (TBL1XR1) is a co-repressor
of nuclear hormone transcription factors and is required for Wnt sig-
naling. Pathogenic de novo variants in the C-terminal WD-40 repeats of
TBL1XR1 have been identified in individuals with autism (O’Roak et al.,
2012) and Pierpont syndrome (Heinen et al., 2016). Saitsu et al.
Table 1
Pathogenic variants and variants of unknown significance (VOUS) identified in this study.
Gene Inheritance Inferred Effect GRCh37/hg19 Genomic Coordinate cDNA Change Protein Change CADD gnomAD(AC)
GNAO1 de novo Likely-pathogenic chr16:g.56368706 G > C NM_138736.2:c.530 G > C p.(Arg177Pro) 35.0 0
KCNB1 de novo Pathogenic chr20:g.47990350 G > A NM_004975.2:c.1747C > T p.(Arg583*)^ 37.0 0
KCNB1 de novo Pathogenic chr20:g.47990988C > T NM_004975.2:c.1109 G > A p.(Trp370*) 39.0 0
SLC35A2 de novo Likely-pathogenic chrX:g.48763706 T > C NM_005660.1:c.389A > G p.(Tyr130Cys) 22.9 0
STXBP1 de novo Likely-pathogenic chr9:g.130416028 T > C NM_003165.3:c.122 T > C p.(Leu41Pro) 24.1 0
TBL1XR1 de novo Likely-pathogenic chr3:g.176771679C > T NM_024665.4:c.86 G > A p.(Gly29Asp) 33.0 0
KIF1A unknown Pathogenic chr2:g.241723197C > T NM_001244008.1:c.757 G > A p.(Glu253Lys)^ 34.0 0
19.7% Mosaic VOUS chr2:g.241662963C > T NM_001244008.1:c.4331 G > A p.(Arg1444Gln) 35.0 1
FASN de novo VOUS chr17:g.80044266 G > A NM_004104.4:c.3596C > T p.(Ala1199Val) 6.06 3
HDAC4 unknown VOUS chr2:g.239990214 G > A NM_006037.3:c.2825C > T p.(Pro942Leu) 20.4 0
PNMAL1 unknown VOUS chr19:g.46973812 T > C NM_018215.3:c.481A > G p.(Ile161Val) 9.21 0
PPP3CA unknown VOUS chr4:g.102015013 G > T NM_000944.4:c.702C > A p.(Asp234Glu) 27.0 0
^, recurrent pathogenic variant.
A.M. Muir, et al. Epilepsy Research 156 (2019) 106181
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identified a girl with West syndrome with a de novo p.Gly70Asp variant
in the N-terminal F-box domain of TBL1XR1 (Saitsu et al., 2014). We
have identified a second individual with West syndrome who has a de
novo p.Gly29Asp variant in the N-terminal LisH domain of TBL1XR1,
strengthening the case for TBL1XR1 as an IS gene.
We also identified a pathogenic variant in kinesin family member
1A (KIF1A), which encodes a neuron-specific microtubule-dependent
molecular motor protein responsible for transport of synaptic vesicle
precursors along axons. Pathogenic de novo variants in the motor do-
main of KIF1A can result in a complex degenerative neurologic phe-
notype characterized by severe developmental delay, and a variable
combination of progressive cerebral and cerebellar atrophy, optic nerve
atrophy, progressive spasticity, hypotonia, and peripheral neuropathy
(Esmaeeli Nieh et al., 2015; Lee et al., 2015). While approximately one
third of individuals with pathogenic heterozygous KIF1A variants have
epilepsy, only one individual, with a diagnosis of PEHO-like syndrome,
has been reported to have IS (Langlois et al., 2016). We identified a
heterozygous p.Glu253Lys variant in the motor domain of KIF1A in a
girl with severe developmental delay and cognitive regression, cere-
bellar atrophy, hypotonia, optic atrophy, and refractory IS. While par-
ental DNA was unavailable, the same variants have been reported as
pathogenic in three other individuals with complex degenerative neu-
rologic phenotypes (Esmaeeli Nieh et al., 2015; Lee et al., 2015). One
previously reported individual with KIF1A p.Glu253Lys had no history
of seizures, one had unspecified seizures, and one had no information
on seizure history available. This coincides with the overall trend of
variable expressivity seen in other recurrent KIF1A variants (Esmaeeli
Nieh et al., 2015; Langlois et al., 2016; Lee et al., 2015). We identified a
second KIF1A variant in this individual, a somatic mosaic p.Arg1444Gln
mutation. This mutation is located outside of the motor domain where
all other pathogenic de novo KIF1A missense variants are located and is
therefore unlikely to have a pathogenic effect on the protein.
The only gene for which we found multiple individuals with de nov
variants was KCNB1, which encodes the Kv2.1 potassium channel
(MIM: 600397). Pathogenic KCNB1 de novo variants have been reported
in several children with neurodevelopmental disorders, 36% of whom
had a history of spasms (de Kovel et al., 2017). The majority of KCNB1
pathogenic variants identified have been missense variants, which tend
to cause intractable epilepsy and severe developmental delay. The few
protein-truncating variants identified have been in individuals with
developmental delay but milder seizure phenotypes (de Kovel et al.,
2017). We identified two individuals with de novo nonsense mutations
in KCNB1, p.Arg583* and p.Trp370*. Both individuals had strikingly
similar seizure histories: spasm onset before 6months of age, seizures
controlled by medication, and the development of no additional seizure
types.
Previous large cohort genetic studies in IS have identified patho-
genic variants in 11–29% of individuals (Boutry-Kryza et al., 2015; Epi
et al., 2013; Michaud et al., 2014). With the exception of CDKL5,
STXBP1, and now KCNB1, no IS study has identified multiple in-
dividuals with de novo variants in the same gene. This has hampered the
identification of novel IS genes. To increase the likelihood of finding
additional cases, we screened genes where a de novo variant had already
been identified in an individual with IS. We were able to identify ad-
ditional pathogenic variants in 2 of 42 candidate IS genes. However, it
is likely that there are additional cases for many of the other candidate
genes. Genetic studies in much larger cohorts or the use of online tools
to connect genetics researchers from around the world will be needed to
identify additional genetic causes of IS.
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